Allison Bratzel
Stock Analyst at Piper Sandler
(4.27)
# 423
Out of 4,918 analysts
39
Total ratings
66.67%
Success rate
12.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $71.95 | +55.67% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $7.60 | +189.47% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $10.49 | +214.74% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $28.44 | +304.36% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $3.72 | +61.29% | 1 | Mar 14, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $3.83 | +578.85% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $672.91 | +7.74% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $15.63 | +40.75% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $21.98 | +4.64% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $43.03 | +44.09% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $42 | $36.46 | +15.19% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $11.31 | +94.52% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $2.28 | +75.44% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $6.83 | +192.83% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $4.24 | +371.70% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $75.59 | +32.29% | 2 | Feb 8, 2023 |
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $71.95
Upside: +55.67%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $7.60
Upside: +189.47%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $10.49
Upside: +214.74%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $28.44
Upside: +304.36%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $3.72
Upside: +61.29%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $3.83
Upside: +578.85%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $672.91
Upside: +7.74%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $15.63
Upside: +40.75%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $21.98
Upside: +4.64%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $43.03
Upside: +44.09%
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $36.46
Upside: +15.19%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.31
Upside: +94.52%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $2.28
Upside: +75.44%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $6.83
Upside: +192.83%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $4.24
Upside: +371.70%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $75.59
Upside: +32.29%